Lung Cancer | Specialty

Pembrolizumab as Treatment for Oligometastatic NSCLC

November 16th 2018

Various Forms of Disease Progression in Advanced NSCLC

November 16th 2018

Second-line Treatment for Nondriver Metastatic NSCLC

November 16th 2018

Immunotherapy Paradigm for Newly Diagnosed NSCLC

November 16th 2018

IMpower131 & KEYNOTE-407/189 Squamous NSCLC Treatments

November 16th 2018

The KEYNOTE-042 and IMpower150 PD-L1 Treatments

November 16th 2018

The KEYNOTE-024 Precedent for Advanced-NSCLC Treatment

November 16th 2018

Dr. Kohman on the NELSON Trial of Lung Cancer Screening

November 15th 2018

Leslie J. Kohman, MD, FACS, Distinguished Service Professor of Surgery, Upstate Medical University, Upstate Cancer Center, discusses the results of the NELSON trial of screening in lung cancer.

Dr. Drilon on Tepotinib and Gefitinib in MET+ EGFR-Mutant NSCLC

November 15th 2018

Alexander E. Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of tepotinib and gefitinib (Iressa) in patients with MET-positive EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Brahmer on the Benefit of Immunotherapy in Metastatic NSCLC

November 15th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the benefit of immunotherapy in the treatment of patients with metastatic non–small cell lung cancer (NSCLC).

Dr. Feldman on the Future of Durvalumab and Tremilimumab in NSCLC

November 14th 2018

Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses the future of durvalumab (Imfinzi) and tremelimumab in non–small cell lung cancer (NSCLC).

More Data Needed on Changing Systemic Therapy in NSCLC

November 13th 2018

There is limited data on when and whether oncologists should change systemic therapy for patients with non–small cell lung cancer, but some studies provide useful guidance.

Biomarkers and Histology Play Key Roles in Frontline Metastatic NSCLC Options

November 13th 2018

In light of recent advancements, the current paradigm for choosing first-line therapy for patients with metastatic non–small cell lung cancer who do not harbor an actionable driver oncogene depends upon PD-L1 expression level and histology.

Herbst Highlights Next Steps With Immunotherapy in Lung Cancer

November 13th 2018

Roy S. Herbst, MD, PhD, discusses where future research is headed for immunotherapy in lung cancer.

Dr. Hanna on Consolidation Immunotherapy in Stage III NSCLC

November 13th 2018

Nasser Hanna, MD, Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research, at Indiana University Melvin and Bren Simon Cancer Center, discusses the efficacy of consolidation immunotherapy in patients with stage III non–small cell lung cancer.

Dr. Herbst on Immune Resistance in Lung Cancer

November 12th 2018

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses mechanisms of immune resistance for patients with lung cancer.

Broad Panel NGS Testing Grows in Value for NSCLC

November 11th 2018

Although driver mutations have been identified for significant NSCLC subsets, patients with metastatic disease benefit from broad panel next-generation sequencing testing because of the growing clinical relevance of less common alterations and gene signatures.

Dr. Perez-Soler on Efficiency of NGS in Lung Cancer

November 11th 2018

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses the efficiency of next-generation sequencing in lung cancer.

Camidge Breaks Down Oncogene-Driven NSCLC

November 11th 2018

D. Ross Camidge, MD, PhD, discusses the crowded landscape of oncogene-driven non­–small cell lung cancer.

Dr. Borghaei on Second-Line Therapy in SCLC

November 10th 2018

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the evolving second line of treatment in small cell lung cancer.